Yungjin Pharm. Co., Ltd. (003520.KS)
KRW 1989.0
(-2.02%)
KRW 1989.0
(-2.02%)
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2023 | 7.64 Billion KRW | 186.38% |
| 2022 | -14.29 Billion KRW | -113.29% |
| 2021 | -6.55 Billion KRW | -175.64% |
| 2020 | 8.27 Billion KRW | -52.45% |
| 2019 | 17.3 Billion KRW | 239.54% |
| 2018 | 4.45 Billion KRW | -48.36% |
| 2017 | 9.85 Billion KRW | -11.94% |
| 2016 | 11.94 Billion KRW | 4.24% |
| 2015 | 11.28 Billion KRW | -8.0% |
| 2014 | 12.03 Billion KRW | -35.77% |
| 2013 | 17.12 Billion KRW | 117.86% |
| 2012 | 8.61 Billion KRW | 2.37% |
| 2011 | 8.21 Billion KRW | 39.65% |
| 2010 | 4.24 Billion KRW | 115.41% |
| 2009 | 1.95 Billion KRW | -58.91% |
| 2008 | 7.76 Billion KRW | 292.27% |
| 2007 | -4.02 Billion KRW | 0.0% |
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2024 Q1 | 6.78 Billion KRW | 349.35% |
| 2024 Q2 | 3.37 Billion KRW | -74.38% |
| 2024 Q3 | 1.32 Billion KRW | -41.23% |
| 2023 Q4 | 4.73 Billion KRW | -73.82% |
| 2023 Q1 | 2.52 Billion KRW | 117.27% |
| 2023 Q2 | 17.23 Billion KRW | 581.63% |
| 2023 FY | - KRW | 186.38% |
| 2023 Q3 | 18.1 Billion KRW | 5.06% |
| 2022 Q3 | -265.41 Million KRW | -169.74% |
| 2022 FY | - KRW | -113.29% |
| 2022 Q1 | 854.2 Million KRW | 182.88% |
| 2022 Q2 | 380.59 Million KRW | -55.44% |
| 2022 Q4 | -14.64 Billion KRW | -5416.26% |
| 2021 Q3 | -2.28 Billion KRW | 22.78% |
| 2021 Q4 | -1.03 Billion KRW | 54.82% |
| 2021 FY | - KRW | -175.64% |
| 2021 Q1 | -143.81 Million KRW | 85.98% |
| 2021 Q2 | -2.95 Billion KRW | -1954.18% |
| 2020 Q3 | 1.44 Billion KRW | -55.86% |
| 2020 Q4 | -1.02 Billion KRW | -170.95% |
| 2020 FY | - KRW | -52.45% |
| 2020 Q1 | 4.77 Billion KRW | 231.0% |
| 2020 Q2 | 3.27 Billion KRW | -31.49% |
| 2019 Q3 | 5.79 Billion KRW | -8.04% |
| 2019 FY | - KRW | 239.54% |
| 2019 Q1 | 4.27 Billion KRW | 11.81% |
| 2019 Q2 | 6.3 Billion KRW | 47.52% |
| 2019 Q4 | 1.44 Billion KRW | -75.1% |
| 2018 Q2 | -829.07 Million KRW | -124.09% |
| 2018 Q1 | 3.44 Billion KRW | 1536.28% |
| 2018 FY | - KRW | -48.36% |
| 2018 Q4 | 3.82 Billion KRW | 422.25% |
| 2018 Q3 | -1.18 Billion KRW | -43.09% |
| 2017 Q4 | -239.62 Million KRW | -108.75% |
| 2017 Q2 | 3.11 Billion KRW | -31.37% |
| 2017 Q1 | 4.54 Billion KRW | 873.87% |
| 2017 Q3 | 2.73 Billion KRW | -12.22% |
| 2017 FY | - KRW | -11.94% |
| 2016 Q3 | 3.98 Billion KRW | 1.58% |
| 2016 Q4 | 466.79 Million KRW | -88.27% |
| 2016 FY | - KRW | 4.24% |
| 2016 Q1 | 3.17 Billion KRW | -2.03% |
| 2016 Q2 | 3.91 Billion KRW | 23.33% |
| 2015 Q2 | 2.1 Billion KRW | -33.33% |
| 2015 Q4 | 3.24 Billion KRW | 25.96% |
| 2015 Q3 | 2.57 Billion KRW | 22.46% |
| 2015 FY | - KRW | -8.0% |
| 2015 Q1 | 3.15 Billion KRW | -3.51% |
| 2014 Q4 | 3.26 Billion KRW | 33.02% |
| 2014 Q3 | 2.45 Billion KRW | 9.14% |
| 2014 Q2 | 2.25 Billion KRW | -44.55% |
| 2014 Q1 | 4.06 Billion KRW | -37.27% |
| 2014 FY | - KRW | -35.77% |
| 2013 FY | - KRW | 117.86% |
| 2013 Q3 | 3.26 Billion KRW | -43.34% |
| 2013 Q2 | 5.76 Billion KRW | 77.64% |
| 2013 Q1 | 3.24 Billion KRW | 5.33% |
| 2013 Q4 | 6.47 Billion KRW | 98.31% |
| 2012 FY | - KRW | 2.37% |
| 2012 Q4 | 3.07 Billion KRW | -30.61% |
| 2012 Q3 | 4.43 Billion KRW | 60.31% |
| 2012 Q2 | 2.76 Billion KRW | 265.76% |
| 2012 Q1 | -1.66 Billion KRW | -183.89% |
| 2011 Q3 | 1.62 Billion KRW | -6.67% |
| 2011 Q1 | 2.82 Billion KRW | 60.9% |
| 2011 Q4 | 1.99 Billion KRW | 22.35% |
| 2011 Q2 | 1.74 Billion KRW | -38.37% |
| 2011 FY | - KRW | 39.65% |
| 2010 Q2 | 4.25 Billion KRW | 259.88% |
| 2010 Q1 | -2.66 Billion KRW | -308.7% |
| 2010 Q4 | 1.75 Billion KRW | -34.08% |
| 2010 Q3 | 2.66 Billion KRW | -37.31% |
| 2010 FY | - KRW | 115.41% |
| 2009 FY | - KRW | -58.91% |
| 2009 Q4 | 1.27 Billion KRW | 138.07% |
| 2009 Q3 | 535.4 Million KRW | 190.26% |
| 2009 Q2 | -593.17 Million KRW | -164.49% |
| 2009 Q1 | 919.72 Million KRW | -31.66% |
| 2008 Q3 | 2.51 Billion KRW | 77.48% |
| 2008 Q4 | 1.34 Billion KRW | -46.49% |
| 2008 Q2 | 1.41 Billion KRW | -6.2% |
| 2008 FY | - KRW | 292.27% |
| 2008 Q1 | 1.51 Billion KRW | 281.02% |
| 2007 Q2 | -6.32 Billion KRW | -915.57% |
| 2007 Q3 | 2.85 Billion KRW | 145.11% |
| 2007 Q1 | 775.25 Million KRW | 0.0% |
| 2007 Q4 | -834.57 Million KRW | -129.26% |
| 2007 FY | - KRW | 0.0% |
| Name | EBITDA | EBITDA Difference |
|---|---|---|
| Yuyu Pharma, Inc. | 4.85 Billion KRW | -57.458% |
| Dong-A Socio Holdings Co., Ltd. | 141.36 Billion KRW | 94.589% |
| Ildong Holdings Co., Ltd. | -64.03 Billion KRW | 111.946% |
| HANDOK Inc. | 35.06 Billion KRW | 78.185% |
| Kukje Pharma Co., Ltd. | -1.03 Billion KRW | 837.991% |
| Yuhan Corporation | 127.43 Billion KRW | 93.997% |
| Dong-A ST Co., Ltd. | 37.52 Billion KRW | 79.612% |
| SAMSUNG PHARM. Co., LTD. | -21.68 Billion KRW | 135.273% |
| Hanmi Pharm. Co., Ltd. | 323.33 Billion KRW | 97.634% |
| Hanall Biopharma Co.,Ltd | 4.99 Billion KRW | -53.293% |
| Ilyang Pharmaceutical Co.,Ltd | 15.11 Billion KRW | 49.4% |
| Dong Sung Bio Pharm.Co.,Ltd. | 3.42 Billion KRW | -123.616% |
| MYUNGMOON Pharm co.,Ltd | 4.52 Billion KRW | -69.005% |
| Hana Pharm Co., Ltd. | 35.48 Billion KRW | 78.443% |
| Yuyu Pharma, Inc. | 4.85 Billion KRW | -57.458% |
| Ilsung Pharmaceuticals Co., Ltd. | -18.47 Billion KRW | 141.414% |
| REYON Pharmaceutical Co., Ltd. | 6.55 Billion KRW | -16.703% |
| Aprogen pharmaceuticals,Inc. | -49.29 Billion KRW | 115.519% |
| JW Holdings Corporation | 187.88 Billion KRW | 95.928% |
| Ildong Pharmaceutical Co., Ltd. | -51.22 Billion KRW | 114.933% |
| Chong Kun Dang Pharmaceutical Corp. | 283.62 Billion KRW | 97.303% |
| JW Pharmaceutical Corporation | 89.22 Billion KRW | 91.426% |
| Shin Poong Pharm.Co.,Ltd. | -37.06 Billion KRW | 120.638% |
| Hyundai Pharmaceutical Co., Ltd. | 13.2 Billion KRW | 42.089% |
| Samil Pharmaceutical Co.,Ltd | 11.82 Billion KRW | 35.324% |
| Jeil Pharmaceutical Co.,Ltd | 18.65 Billion KRW | 58.993% |
| Yuyu Pharma, Inc. | 4.85 Billion KRW | -57.458% |
| Kwang Dong Pharmaceutical Co., Ltd. | 54.97 Billion KRW | 86.084% |
| Daewoong pharmaceutical Co.,Ltd | 164.91 Billion KRW | 95.361% |
| JW Pharmaceutical Corporation | 89.22 Billion KRW | 91.426% |
| Yuhan Corporation | 127.43 Billion KRW | 93.997% |
| Jeil Pharma Holdings Inc | 33.47 Billion KRW | 77.148% |
| Suheung Co., Ltd. | 77.02 Billion KRW | 90.069% |
| JW Pharmaceutical Corporation | 89.22 Billion KRW | 91.426% |
| Samjin Pharmaceuticals Co., Ltd. | 36.63 Billion KRW | 79.118% |
| Korea United Pharm Inc. | 70.78 Billion KRW | 89.192% |
| CKD Bio Corp. | -1.63 Billion KRW | 569.187% |
| Daewon Pharmaceutical Co., Ltd. | 49.79 Billion KRW | 84.637% |
| Dongwha Pharm.Co.,Ltd | 32.56 Billion KRW | 76.506% |
| Whan In Pharm Co.,Ltd. | 36.81 Billion KRW | 79.218% |
| Shin Poong Pharm.Co.,Ltd. | -37.06 Billion KRW | 120.638% |
| Chong Kun Dang Holdings Corp. | 62.28 Billion KRW | 87.718% |
| Boryung Corporation | 114.28 Billion KRW | 93.307% |
| Bukwang Pharmaceutical Co., Ltd. | -30.56 Billion KRW | 125.025% |
| Ilyang Pharmaceutical Co.,Ltd | 15.11 Billion KRW | 49.4% |
| JW Lifescience Corporation | 50.82 Billion KRW | 84.95% |